Stay updated on Pembrolizumab Post-TACE in Liver Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    Revision label updated from v3.3.3 to v3.3.4 in the page footer.
    Difference
    0.1%
    Check dated 2026-01-15T12:57:04.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    No Change Detected
  5. Check
    31 days ago
    Change Detected
    Summary
    Footer now displays Revision: v3.3.3; the HHS Vulnerability Disclosure link and the previous Revision: v3.3.2 reference were removed.
    Difference
    0.1%
    Check dated 2025-12-17T22:04:46.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    Publications section text was updated to clarify auto-fill from PubMed, and the revision/version numbers were updated from v3.2.0 to v3.3.2.
    Difference
    0.1%
    Check dated 2025-11-26T08:26:59.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    Removed the government funding lapse notice from the study page, which previously directed users to official status pages for operating updates.
    Difference
    0.4%
    Check dated 2025-11-19T07:56:09.000Z thumbnail image
  8. Check
    82 days ago
    Change Detected
    Summary
    New entries appear in the Study Record Dates showing Results First Submitted (2024-05-13), Results First Submitted that Met QC Criteria (2025-01-07), and Results First Posted (2025-02-03).
    Difference
    0.5%
    Check dated 2025-10-28T02:55:15.000Z thumbnail image
  9. Check
    104 days ago
    Change Detected
    Summary
    - Added a government operating status notice and a version bump to v3.2.0. - Removed the old version tag v3.1.0.
    Difference
    4%
    Check dated 2025-10-06T15:55:49.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Post-TACE in Liver Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.